Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 5, May, p. 565–572

doi: 10.17219/acem/119383

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Upregulated sulfatase and downregulated MMP-3 in thoracic aortic aneurysm

Małgorzata Matusiewicz1,A,B,C,D,E,F, Maciej Rachwalik2,A,B,C,E,F, Małgorzata Krzystek-Korpacka1,B,C,E,F, Grzegorz Bielicki2,B,F, Izabela Berdowska1,C,E,F, Rafał Nowicki2,B,F, Andrzej Gamian1,3,A,E,F, Marek Jasiński2,C,E,F

1 Department of Medical Biochemistry, Wroclaw Medical University, Poland

2 Department and Clinic of Cardiac Surgery, Wroclaw Medical University, Poland

3 Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Abstract

Background. Thoracic aortic aneurysm (TAA) formation is accompanied by degradation of extracellular matrix components (EMC). Numerous matrix metalloproteinases (MMPs) have been implicated in the process, but the involvement of MMP-3 remains unclear. Additionally, the changes in proteoglycan (PG) structure can alter the signal transduction pathways in TAA, though the enzymatic systems which originate them are not fully understood.
Objectives. To measure MMP-3 and sulfatase levels in aneurysmal tissue, comparing them with non-aneurysmal vessels, and to investigate possible correlations with patients’ serum levels in order to evaluate their potential usefulness in aiding aneurysm detection and monitoring.
Material and Methods. The study included 74 patients (TAA: n = 42; control group: n = 32). Sulfatase activity was measured colometrically and MMP-3 levels were measured immunoenzymatically.
Results. Sulfatase activities were higher (p = 0.03) and MMP-3 concentrations lower (p = 0.014) in aneurysmal tissue than in normal aortic tissue. Medium-sized dilatations were associated with lower tissue MMP-3 concentrations than small dilatations (p = 0.033). No differences in sulfatase activity or MMP-3 concentration in the serum of TAA patients were observed in comparison with the controls. The serum and tissue levels of MMP-3 were correlated (r = 0.41; p < 0.001). The serum levels of MMP-3 were significantly lower in the female patients than in the male patients (p = 0.006).
Conclusion. Our studies confirmed the lower MMP-3 levels in aneurysmal tissue, but the lack of a statistically confirmed reduction of MMP-3 in the blood serum seems to preclude its usefulness for diagnostic purposes. Our study points to the differences in MMP-3 behavior between TAA and abdominal aortic aneurysms. Significantly higher sulfatase activity in TAA tissue suggests a possible impact of sulfatase on signal transduction pathways involved in aneurysm formation.

Key words

metalloproteinases, ascending aortic aneurysm, matrix metalloproteinase-3, sulfatases, thoracic aortic aneurysm

References (40)

  1. Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aneurysm progression. J Surg Res. 2007;139(2):292–307.
  2. Curci JA. Digging in the “soil” of the aorta to understand the growth of abdominal aortic aneurysms. Vascular. 2009;17(Suppl 1):S21–S21.
  3. Jones JA, Beck C, Barbour JR, et al. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: Myofibroblast-mediated vascular remodeling. Am J Pathol. 2009;175(4):1746–1756.
  4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function and biochemistry. Circ Res. 2003;92(8):827–839.
  5. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol. 2004;24:54–60.
  6. Johnson JL, Dwivedi A, Somerville M, et al. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol. 2011;31(9):e35–e44.
  7. Patel MI, Melrose JJ, Ghosh P, Appleberg M. Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg. 1996;24(1):82–92.
  8. Lesauskaite V, Tanganelli P, Sassi C, et al. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: Morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol. 2001;32(9):1003–1011.
  9. Sinha I, Bethi S, Cronin P, et al. A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: A role for matrix metalloproteinase 9 and 2. J Vasc Surg. 2006;43(2):342–348.
  10. Cheung YF, Chow PC, So EK, Chan KW. Circulating transforming growth factor-β and aortic dilation in patients with repaired congenital heart disease. Sci Rep. 2019;9(1):162. doi:10.1038/s41598-018-36458-1
  11. Ikonomidis JS, Jones JA, Barbour JR, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006;114(Suppl 1):I-365-I-370.
  12. Rabkin SW. Differential expression of MMP-2, MMP-9 and TIMP proteins in thoracic aortic aneurysm: Comparison with and without bicuspid aortic valve. A meta-analysis. Vasa. 2014;43(6):433–442.
  13. Kowalewski R, Sobolewski K, Małkowski A, Wolańska M, Gacko M. Evaluation of enzymes involved in proteoglycans degradation in the wall of abdominal aortic aneurysms. J Vasc Res. 2006;43(1):95–100.
  14. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: Single-centre randomized controlled trial. BMJ. 2005;330(7494):750. doi:10.1136/bmj.38369.620162.82
  15. Lindholt JS. Abdominal aortic aneurysms. Dan Med Bull. 2010;57:B4219.
  16. Singh J, Tavella D, Di Ferrante N. Measurements of arylsulfatases A and B in human serum. J Pediatrics. 1975;86(4):574–576.
  17. Morimoto-Tomita M, Uchimura K, Werb Z, et al. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem. 2002;277(51):49175–49185.
  18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
  19. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996;271(17):10079–10086.
  20. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta 1 release. Biochem J. 1997;322(Pt 3):809–814.
  21. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-binding growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 1997;272(50):31730–31737.
  22. Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001;114(Pt 1):111–118.
  23. Ikonomidis JS, Jones JA, Barbour JR, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007;133(4):1028–1036.
  24. Jones JA, Zavadzkas JA, Chang EI, et al. Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg. 2010;140(3):653–659.
  25. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21(9):1140–1145.
  26. Karapanagiotidis GT, Antonitsis P, Charokopos N, et al. Serum levels of matrix metalloproteinases-1, -2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiovasc Surg. 2009;4:59.
  27. Carrel TWG, Burnand KG, Wells GMA, Clements JM, Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation. 2002;105(4):477–482.
  28. Hadi T, Boytard L, Silvestro M, et al. Macrophage-derived netrin-1 promotes abdominal aortic aneurysm formation by activating MMP3 in vascular smooth muscle cells. Nat Commun. 2018;9(1):5022. doi:10.1038/s41467-018-07495-1
  29. Della Corte A, Quarto C, Bancone C, et al. Spatiotemporal patterns of smooth muscle cell changes in ascending aortic dilatation with bicuspid and tricuspid aortic valve stenosis: Focus on cell-matrix signaling. J Thorac Cardiovasc Surg. 2008;135(1):8–18,e1–2.
  30. Rowe VL, Stevens SL, Reddick TT, et al. Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas. J Vasc Surg. 2000;31(3):567–576.
  31. Wight TN, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis. Key roles for versican. Circ Res. 2004;94(9):1158–1167.
  32. Iozzo RV. The biology of small leucine-rich proteoglycans: Func­tional network of interactive proteins. J Biol Chem. 1999;274(27):18843–18846.
  33. Theocharis AD, Tsolakis I, Tsegenidis T, Karamanos NK. Human abdominal aortic aneurysm is closely associated with compositional and specific modifications at the glycosaminoglycan level. Atherosclerosis. 1999;145(2):359–368.
  34. Theocharis AD, Theocharis DA, De Luca G, Hjerpe A, Karamanos NK. Compositional and structural alternations of chondroitin and dermatan sulfates during the progression of atherosclerosis and aneurismal dilatation of the human abdominal aorta. Biochimie. 2002;84(7):667–674.
  35. Buono M, Cosma MP. Sulfatase activities towards the regulation of cell metabolism and signaling in mammals. Cell Mol Life Sci. 2010;67(5):769–780.
  36. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. ­Enzymatic remodeling of heparan sulfate proteoglycans within the tumor micro­environment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005;96(5):897–905.
  37. Chen Q, Sivakumar P, Barley C, et al. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-β (TGF-β) by modulating assembly of latent TGF-β-binding protein-1. J Biol Chem. 2007;282(36):26418–26430.
  38. Powell JT, Länne T. Through thick and thin collagen fibrils, stress and aortic rupture: Another piece in the jigsaw. Circulation. 2007;115(21):2687–2688.
  39. Jones JA, Barbour JR, Stroud RE, et al. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res. 2008;45(6):457–468.
  40. Wang Y, Ait-Oufelia H, Herbin O, et al. TGF-β activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120(2):422–432.
© Wroclaw Medical University